Hey finish - I'm jammed for time but here is a combination of a few posts to help bring you up to speed from my perspective - not pumping, I'm a share holder, but you asked and I'm trying to help you by responding.
March 23 #28885
Hey Steve - I disagree - I don't see it as pumping to state facts and you have furnished us with many, along with your opinions based on those. Pumping? No. What has always bothered me is the 'dumping' in conflict with the reality of BIEL. Yes, there are management issues that need addressing, but the company will not be selling Whelans, and the FDA is not assessing approvals of Whelans - BIEL involves ActiPatch, ALLAY, RecoveryRx and many others in the product line.
I posted to you the following message on January 17 based on what I understood to be the facts at that moment in time. A lot has happened since then including a doubling in SP. If BIEL and its BOD can get help on the management horsepower side and the FDA approvals I think it deserves, along with other companies in the PEMF device space, my opinion is this puppy will fly. Is that pumping? Or, closer to reality than simply pounding something for the sake of pounding it.
SENT EARLIER January 17 to Steve43
Hey Steve - when you mention all the countries that have issued OTC regulatory approval for BIEL's product line, like Health Canada and in the UK, please don't forget the FDA here at home. The FDA has approved BIEL's 'RecoveryRx' product as a healing accelerator device for post-op opthalmic surgery patients, when prescribed, with remarkable results. Imagine that!
But, now, I choose to completely ignore the almost OCD naysayers and stick solely with the facts of BIEL products.
Fact - ActiPatch really works well - I know first-hand because I used it on a serious injury and my doctor could not believe the results;
Fact - it is financially affordable;
Fact - it is not a drug, no chemicals rampant with side-effects;
Fact - there has never been one, not one, negative side-effect, imagine a BIEL TV slot - "sorry no negative side-effects";
Fact - we, along with BIEL management, must be patient, success takes time;
Fact - BIEL's management could have done several things differently, but we don't know anything about the decisions they faced and why, so we should have no comment now about the past;
Fact - the FDA didn't get it right first time either, it's new, and the FDA is now re-assessing all PEMF devices;
Fact - many very, very bright, articulate scientists have put their knowledge and wisdom forward in support of BIEL and other firms; and
Fact - I have said all this before, as have many posters here, and not one naysayer has refuted one word of the facts.
THEN March 23 #28887
OK Steve - in the last couple of hours, diarch asked in a post what BIEL might be worth in a best-case scenario and asked if perhaps 2 bits might be a realistic number.
yankee55 asked about thoughts/reasons for the recent upside move.
My last post set out some, not all current goings on like - the Gro-International deal Feb 14 for the EU and Africa, London England Gala BIEL received runner up device award to the Boots no-touch thermometer, the recent publicity at Johns Hopkins gala and it was just that - good publicity bought or not, the upcoming public meeting hosted by the USFDA in a couple of weeks on April 5th and the fact that the FDA apparently admitted they did not have the scientific horsepower in-house to assess electronic devices and were going to hire 200 people (I liked the honesty of that, if true!)....
Then you opined in your last post about 20 cents, without FDA approval.
Would you please share your thoughts if BIEL does get OTC approval for its devices? Remembering that so much of the regulatory approval process is avoiding getting a permanent 'no'.
In other words, "we ain't dead yet". And if your opinion is 1 cent, 3 cents, or $3.00 WITH FDA approval, in other words, the best-case scenario diarch asked for, please be frank.
You may wish to couch your opinion with a 2-stage scenario. For instance, the public meeting doesn’t produce a yes or a no for the numerous companies applying for OTC approval for their devices, but the FDA takes everything under advisement which, in essence, means we ain’t dead yet and the company lives to fight another day in the painful approval process. Ughhh.....
Give it your best shot steve - thanks
THEN March 23 #28888
Oooops, almost forgot these two facts!
Alex Gorsky was recently appointed, let's see, Chairman BOD, CEO, Chairman of the Executive Committee of J&J. His previous assignment was Director of the J&J devices division. I just looked at the list and mini-bios of J&J's 13 directors - do you think just one of those trememndously accomplished people might just ask the question, "should we increase our presence in the pain treatment device space?"
Then the other fact is that Gregor Forbes, heading up Gro-International, while he doesn't have the guns of Alex Gorsky, does have 28 years in the OTC pharma space, 25 of them with P&G.
None of this is to say anything is in the wind or I'm pumping anything, I just find it interesting and nothing would suprise me given that BIEL products are drug free, treat pain and promote healing of compromised tissue. The FDA has already approved that RecoveryRX is safe when prescribed to post-op patients having opthalmic surgery. That would be the eye area, close to the brain!
And if I'm Whelan at BIEL, I'm talking to both J&J and P&G to at least keep the lines of communication open. I see Whelan as a stubborn, somewhat aging ex-US Marine, who for a time probably wanted to go it alone, Founder's Syndrome, but even those types have to eat and Whelan could eat very, very well, as I see it.
Cheers finish - hope this helps
AI
